古塞奇尤单抗抑制活动性银屑病关节炎结构损伤进展:APEX 研究第24周结果
APEX 是一项正在进行的3b期随机双盲安慰剂对照研究,纳入1020例未使用过生物制剂的活動性银屑病关节炎成人患者,按5:7:7随机分配至古塞奇尤单抗100 mg每4周组、古塞奇尤单抗100 mg第0、4周后每8周组或安慰剂组。第24周时,古塞奇尤单抗每4周组(66.6%)和每8周组(68.3%)达到ACR20的比例显著高于安慰剂组(47.0%),且两组总vdH-S评分最小二乘均值变化(0.55和0.54)显著低于安慰剂组(1.35)。
要点
- 第24周ACR20:古塞奇尤单抗每4周组66.6%、每8周组68.3%,均显著高于安慰剂组47.0%(均P<0.001)。
- 第24周总vdH-S评分最小二乘均值变化:每4周组0.55、每8周组0.54,均显著低于安慰剂组1.35(P=0.002和P<0.001)。
- 截至第24周,每4周组、每8周组和安慰剂组分别有38.2%、42.5%和37.3%的参与者出现至少1次不良事件,未见新的安全性信号。
核心结论
- 在未使用过生物制剂的活動性、侵蚀性银屑病关节炎参与者中,古塞奇尤单抗在第24周较安慰剂显著提高临床改善率并显著抑制结构损伤进展,未见新的安全性信号。
研究设计与样本
- APEX为正在进行的3b期随机双盲安慰剂对照研究,将未使用过生物制剂的活動性银屑病关节炎成人按5:7:7随机分配至古塞奇尤单抗100 mg每4周组、古塞奇尤单抗100 mg第0周和第4周后每8周组或安慰剂每4周组。
- 纳入标准为≥3个压痛关节、≥3个肿胀关节、C反应蛋白≥0.3 mg/dL且≥2个侵蚀性关节。
- 共纳入1020例参与者:每4周组273例、每8周组371例、安慰剂组376例。
主要发现
- 第24周达到ACR20的比例:古塞奇尤单抗每4周组66.6%、每8周组68.3%,均显著高于安慰剂组47.0%(均P<0.001)。
- 基线总vdH-S平均评分在各组为26.7至27.7;第24周总vdH-S评分最小二乘均值变化:每4周组0.55、每8周组0.54,均显著低于安慰剂组1.35(P=0.002和P<0.001)。
- 截至第24周出现至少1次不良事件的参与者比例:每4周组38.2%、每8周组42.5%、安慰剂组37.3%,未见新的安全性信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The APEX study evaluated the effects of guselkumab, a fully human, dual-acting monoclonal antibody able to bind CD64 and selectively inhibit the interleukin (IL)-23p19 subunit, on clinical and radiographic outcomes in active psoriatic arthritis (PsA). METHODS: APEX (ongoing, phase 3b, double-blind, placebo-controlled) randomised (5:7:7) biologic-naïve adults with active PsA (≥3 tender, ≥3 swollen joints; C-reactive protein ≥0.3 mg/dL; ≥2 erosive joints) to subcutaneous guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at week 0, week 4, then every 8 weeks (Q8W); or placebo every 4 weeks. Primary (proportion of participants achieving ≥20% improvement in American College of Rheumatology response criteria [ACR20]) and major secondary (total PsA-modified van der Heijde-Sharp [vdH-S] score least squares mean [LSM] change from baseline) endpoints at week 24 were multiplicity-controlled for comparing each guselkumab group versus placebo. RESULTS: Among 1020 participants (Q4W: 273; Q8W: 371; placebo: 376), significantly greater proportions of participants receiving guselkumab Q4W (66.6%) and Q8W (68.3%) versus placebo (47.0%) achieved ACR20 at week 24 (both P < 0.001). Baseline mean total vdH-S scores were 26.7 to 27.7 across groups; guselkumab Q4W- and Q8W-treated participants exhibited significantly lower rates of radiographic progression versus placebo at week 24 (total vdH-S score LSM change: 0.55 and 0.54 vs 1.35; P = 0.002 and P < 0.001, respectively). Through week 24, 38.2%, 42.5%, and 37.3% of participants receiving guselkumab Q4W, Q8W, and placebo, respectively, had ≥1 adverse event, with no new safety signals. CONCLUSIONS: Guselkumab, a fully human monoclonal antibody able to bind CD64 and simultaneously inhibit the IL-23p19 subunit, provided significantly higher rates of clinical improvement and significant inhibition of structural damage progression versus placebo, with no new safety signals, at week 24 in biologic-naïve participants with active and erosive PsA.
引用
- Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study. Ann Rheum Dis. 2025. PMID: 40962616. doi:10.1016/j.ard.2025.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。